Trial Profile
A Phase 2 Single Arm Study to Investigate the Safety and Clinical Activity of Idelalisib Alone and in Combination With Rituximab in Elderly Subjects With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 12 Dec 2017 Results (n=853) of ad hoc analysis assessing rates of grade more than or equal to 3 transaminase elevation using patient data from this and other 5 trials presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 07 Jun 2016 Results of post-hoc analysis of this and other trials (n=1073) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 16 May 2016 Results of long-term follow-up analysis (n=40) published in the Cancer